Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib study of GMDTC in people with excessive cadmium levels
NCT06199349Phase 1Completed
- Start
- Jan 2024
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in cadmium poisoning comparing GMDTC Group with Placebo Group (2 arms). Primary endpoint: Adverse events at 30 days. Started Jan 2024; status: completed.
02
Drugs
gmdtc
03
Conditions
cadmium poisoning
Beyond the preview
Go deeper on NCT06199349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06199349.